Snyder Douglas B. 4

What Happened

• Douglas B. Snyder, SVP and General Counsel of IDEAYA Biosciences (IDYA), was granted a 130,000‑share derivative award (reported as acquired at $0.00) on January 30, 2026. The filing also reports two prior purchases under the company's Employee Stock Purchase Plan (ESPP): 1,039 shares on 2025‑05‑30 at $16.91 ($17,566) and 1,041 shares on 2025‑11‑28 at $16.91 ($17,600), together about $35,166. The 130,000‑share item is a derivative award (an option per the footnote) with a multi‑year vesting schedule, not a cash sale.

Key Details

• Primary grant: 130,000 shares (derivative) acquired 2026‑01‑30; reported price $0.00.
• ESPP purchases: 1,039 shares on 2025‑05‑30 at $16.91 ($17,566) and 1,041 shares on 2025‑11‑28 at $16.91 ($17,600).
• Vesting: Footnote states the grant is subject to an option vesting schedule — 25% vests on the first anniversary measured from Jan 1, 2026, then 1/48th of the total vests monthly, with full vesting on the fourth anniversary of that date.
• Footnotes: ESPP purchases were exempt under Rules 16b‑3(d) and 16b‑3(c).
• Shares owned after the transactions: Not specified in the provided filing excerpt.
• Timeliness: Form 4 was filed 2026‑02‑02 for the 2026‑01‑30 transaction; this appears to be timely under the Form 4 two‑business‑day requirement.

Context

• The 130,000‑share item is a time‑vesting option award (derivative). It does not indicate an immediate sale — shares will vest over years per the schedule and would need to be exercised/held/sold later.
• The ESPP purchases are routine employee purchases (small dollar amounts) and are different from a market purchase that might signal near‑term bullishness.
• These transactions are executive compensation and grants rather than open‑market buys; they should be interpreted as compensation/retention tools unless future trades (exercises or sales) are reported.